Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "ECHO"

46 News Found

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction
Healthcare | August 21, 2025

SIMS Hospital successfully treats rare skin tumour with skull and scalp reconstruction

The patient had been battling DFSP for over eight years, enduring multiple recurrences despite three previous surgeries


Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation
News | June 27, 2025

Star Health Insurance partners with Medi Assist to transform claims through AI and Digital Innovation

Star Health Insurance is modernising its claims ecosystem to be future-ready


Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador
News | June 13, 2025

Cipla Health launches a new campaign for Cipladine with Neena Gupta as brand ambassador

Conceptulised by Lowe Lintas, the new campaign creatively brings the "fast action" benefit of Cipladine to life through a series of films


Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases
News | June 10, 2025

Cadila launches beta-blocker Biscado for treatment of cardiovascular diseases

Bisoprolol is a highly cardioselective beta-1 adrenergic blocker used to manage high blood pressure,


Vgenomics and Meril Genomics collaborate to revolutionise precision medicine
Biotech | April 22, 2025

Vgenomics and Meril Genomics collaborate to revolutionise precision medicine

Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide


M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness
News | February 02, 2025

M. S. Dhoni and Emcure's Namita Thapar unite to champion women's health awareness

Arth by Emcure is a specialized range of supplements designed to address the unique health and wellness needs of women, enabling them to lead healthier and happier lives across all stages


Calquence combination approved in US for untreated mantle cell lymphoma
Drug Approval | January 18, 2025

Calquence combination approved in US for untreated mantle cell lymphoma

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone


Calquence granted priority review in US for patients with untreated mantle cell lymphoma
Drug Approval | October 06, 2024

Calquence granted priority review in US for patients with untreated mantle cell lymphoma

Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy